INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02FWFogarty Patrick W0B / 150S150 trades$600K
  3. 03SPSaba Capital Management, L.P.65B / 19S · 11 late84 trades$21.64M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SJSheena Jonathan0B / 45S45 trades$3.01M
  8. 08SISarowitz Steven I2B / 34S36 trades$22.46M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

72,525 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
RG
Russotti GregorySee Remarks
IPSCCentury Therapeutics, Inc.
Grant or award
A—
265.0K sh
Feb 2, 2026Feb 4, 2026
Page 1379 of 1814
← PrevNext →
traded Feb 2, 2026
+2d
SEC Form 4

Evidence

5
CD
Carr DouglasSVP Finance & Operations
IPSCCentury Therapeutics, Inc.
Grant or award
A—
225.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
SC
Saldanha CraigChief Product Officer
YELPYELP INC
Open-market sale · 10b5-1 plan
SELL$33K
1,200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
CC
Cowan ChadChief Scientific Officer
IPSCCentury Therapeutics, Inc.
Grant or award
A—
265.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
ZN
Zojwalla NaseemCHIEF MEDICAL OFFICER
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
250.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
ZN
Zojwalla NaseemCHIEF MEDICAL OFFICER
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
106.3K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
CT
Chuang Patrick T.Senior VP, Memory Design
GSITGSI TECHNOLOGY INC
Grant or award
A—
20.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
PB
Pfeiffenberger BrentDirector, President and CEO
IPSCCentury Therapeutics, Inc.
Grant or award
A—
945.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NP
Naude PierreDirector
NCNOnCino, Inc.
Grant or award
A—
3,516 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
204.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
HL
Heeson LeeEVP, Head of Incyte Intl
INCYINCYTE CORP
Tax withholding
F$11K
111 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
136.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Grant or award
A—
150.0K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
NA
Novack Jeffrey AdamSecretary and General Counsel
CDNACareDx, Inc.
Grant or award
A—
4,342 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$6,477
2,540 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
136.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
204.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

3
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$20K
1,700 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

3
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$30K
2,797 sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

3
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$50K
4,844 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
15.2K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
HK
Holleran KevinDirector, President and CEO
HAYWHayward Holdings, Inc.
Option exercise · 10b5-1 plan
M$73K
52.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
6,017 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
250.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
106.3K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
6,742 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
SN
Sieffert Kristen NPresident
FOAFinance of America Companies Inc.
Open-market sale · 10b5-1 plan
SELL$17K
750 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$75K
381 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$1,398
556 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

1
BM
Barrett David MichaelDirector, Chief Executive Officer
EXFYExpensify, Inc.
Open-market sale · 10b5-1 plan
SELL$44K
30.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
OO
Okupe OluyemiChief Financial Officer
HIMSHims & Hers Health, Inc.
Option exercise · 10b5-1 plan
M—
5,262 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

0
WS
Wampler Kira SchererDirector
DOCSDoximity, Inc.
Option exercise · 10b5-1 plan
M—
2,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
TS
Tang StanleyDirector
DASHDoorDash, Inc.
Other acquisition or disposition · 10b5-1 plan
J—
45.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
WS
Wampler Kira SchererDirector
DOCSDoximity, Inc.
Option exercise · 10b5-1 plan
M—
2,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
AL
Alpern Paul LVP and General Counsel
AIPArteris, Inc.
Option exercise · 10b5-1 plan
M$2,800
5,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
HK
Holleran KevinDirector, President and CEO
HAYWHayward Holdings, Inc.
Option exercise · 10b5-1 plan
M—
52.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
AL
Alpern Paul LVP and General Counsel
AIPArteris, Inc.
Option exercise · 10b5-1 plan
M—
5,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
FA
Fang AndyDirector
DASHDoorDash, Inc.
Other acquisition or disposition · 10b5-1 plan
J—
10.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
WS
Wampler Kira SchererDirector
DOCSDoximity, Inc.
Derivative conversion · 10b5-1 plan
C—
2,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence